News coverage about Derma Sciences (NASDAQ:DSCI) has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Derma Sciences earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 44.7307593405178 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

ILLEGAL ACTIVITY NOTICE: “Derma Sciences (DSCI) Receiving Somewhat Positive Media Coverage, Accern Reports” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://theolympiareport.com/2017/11/02/derma-sciences-dsci-receiving-somewhat-positive-media-coverage-accern-reports.html.

Derma Sciences Company Profile

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insider Buying and Selling by Quarter for Derma Sciences (NASDAQ:DSCI)

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.